Invasive Candida Infections in Cancer Patients
Author Information
Author(s): Girmenia Corrado, Finolezzi Erica, Federico Vincenzo, Santopietro Michelina, Perrone Salvatore
Primary Institution: Università Cattolica del Sacro Cuore
Hypothesis
What are the current epidemiological patterns and therapeutic options for invasive candidiasis in patients with hematological malignancies and hematopoietic stem cell transplant recipients?
Conclusion
The incidence of invasive Candida infections has decreased in patients with hematological malignancies and HSCT recipients, but the mortality rate remains high.
Supporting Evidence
- The incidence of invasive candidiasis has decreased due to antifungal prophylaxis.
- Non-albicans Candida species are increasingly responsible for candidemia.
- High mortality rates persist despite the introduction of new antifungal agents.
- Prolonged neutropenia is a significant risk factor for invasive fungal diseases.
Takeaway
Doctors are studying how to prevent and treat serious infections caused by Candida in cancer patients, and they found that while these infections are less common now, they can still be very dangerous.
Methodology
The study summarizes epidemiological and therapeutic aspects of candidemia in HM patients and HSCT recipients based on recent literature.
Potential Biases
The reliance on retrospective data may introduce bias in understanding the true epidemiology and outcomes of candidemia.
Limitations
Most data are derived from retrospective studies, and there is a lack of prospective data specifically focused on HM and HSCT populations.
Participant Demographics
The study includes patients with hematological malignancies and those undergoing hematopoietic stem cell transplantation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website